Scarica l'app Stockscreener
0.2718
5.74%
-0.0173
Precedente Chiudi:
$0.2891
Aprire:
$0.2899
Volume 24 ore:
3.71M
Relative Volume:
0.28
Capitalizzazione di mercato:
$4.08M
Reddito:
-
Utile/perdita netta:
$-11.53M
Rapporto P/E:
-0.0564
EPS:
-4.82
Flusso di cassa netto:
$-11.12M
1 W Prestazione:
+12.60%
1M Prestazione:
+13.68%
6M Prestazione:
-68.71%
1 anno Prestazione:
-86.93%
Intervallo 1D:
$0.27
$0.2899
Intervallo di 1 settimana:
$0.2548
$0.33
Portata 52W:
$0.15
$3.10
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Nome
Processa Pharmaceuticals Inc
Settore
Industria
Telefono
443-776-3133
Indirizzo
7380 COCA COLA DRIVE, HANOVER
Confronta PCSA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.2717 | 4.08M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.90 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.64 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.58 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
561.89 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.62 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-25 | Iniziato | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Borsa (PCSA) Ultime notizie
Processa Pharmaceuticals Announces Public Offering Pricing - TipRanks
Processa inks licensing deal with Intact for gastroparesis drug By Investing.com - Investing.com India
Processa Pharmaceuticals (PCSA) Sets Public Offering Price at $0 - GuruFocus
Processa Pharmaceuticals Signs Binding Term Sheet Granting - GlobeNewswire
Processa Pharmaceuticals (PCSA) Enters Licensing Agreement for G - GuruFocus
Processa Pharmaceuticals Prices of $7 Million Public Offering - citybiz
Processa inks licensing deal with Intact for gastroparesis drug - Investing.com
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering | PCSA Stock News - GuruFocus
Processa Pharmaceuticals (PCSA) Announces Public Offering Pricin - GuruFocus
Processa Pharmaceuticals Prices $7 Million Public Offering - MarketScreener
Processa Pares Gains on Equity Offer News - MarketWatch
Processa Pharmaceuticals (PCSA) Announces Public Offering Pricing | PCSA Stock News - GuruFocus
Processa sells 28M shares at 25c in public offering - TipRanks
Processa sees 28M shares at 25c in public offering - TipRanks
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering - GlobeNewswire
Processa Pharmaceuticals Secures $7M Funding: Next-Generation Cancer Drug Trial Gets Green Light - Stock Titan
Processa Pharmaceuticals Announces Licensing Deal with Intact - TipRanks
Processa Pharmaceuticals (PCSA) Shares Soar 150% On Gastroparesis Drug Deal - Benzinga
Processa Pharmaceuticals Grants Intact Therapeutics Exclusive Option to License Gastroparesis Drug Candidate; Shares Rise - marketscreener.com
Processa Pharmaceuticals Skyrockets on Game-Changing Gastroparesis Deal - RagingBull
Processa Pharmaceuticals signs binding term sheet with Intact Therapeutics - TipRanks
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate - Yahoo Finance
Processa Pharmaceuticals (NASDAQ:PCSA) Trading Down 12.9% – Time to Sell? - Defense World
Navigating PCSA’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025 - GlobeNewswire
Processa Pharmaceuticals (PCSA) Prepares for Strategic Insights at BIO Convention 2025 | PCSA Stock News - GuruFocus
Processa to engage potential partners, investors at BIO International Convention - TipRanks
Processa Pharmaceuticals to Engage Potential Partners and Invest - GuruFocus
PCSA Stock Placement by H.C. Wainwright & Co. | PCSA Stock News - GuruFocus
Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention - Nasdaq
Next-Gen Cancer Drug Developer Processa Pharma Eyes Strategic Partners at Major BIO Convention - Stock Titan
Processa Pharmaceuticals presents cancer drug advances at ASCO By Investing.com - Investing.com South Africa
Processa Pharmaceuticals (PCSA) Highlights Cancer Drug Advances at ASCO 2025 | PCSA Stock News - GuruFocus
Processa Pharmaceuticals Announces Presentation and Publication - GuruFocus
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting | PCSA Stock News - GuruFocus
Processa Pharmaceuticals presents cancer drug advances at ASCO - Investing.com Australia
Processa Pharmaceuticals Highlights Next Generation Cancer Therapies with Three Accepted Abstracts at 2025 ASCO Annual Meeting - Nasdaq
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting - GlobeNewswire
Latest Clinical Trial Data: Processa Presents 3 Cancer Treatment Breakthroughs at ASCO 2025 - Stock Titan
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 1.5% – What’s Next? - Defense World
Processa Pharmaceuticals faces Nasdaq delisting risk over share price - MSN
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 - Barchart.com
PCSAProcessa Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
There is no way Processa Pharmaceuticals Inc (PCSA) can keep these numbers up - Sete News
Processa Pharmaceuticals (PCSA) Expected to Announce Earnings on Friday - Defense World
Processa Pharmaceuticals Inc: Rising -91.68% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Taking a Closer Look At Processa Pharmaceuticals Inc (PCSA) Following Its Recent Trade - knoxdaily.com
Processa Pharmaceuticals Inc [PCSA] Shares Rise 8.43 % on Wednesday - knoxdaily.com
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
Processa Pharmaceuticals Inc (PCSA) can make a big difference with a little luck - Sete News
A Closer Look at Processa Pharmaceuticals Inc (PCSA) Stock Gains - investchronicle.com
Processa Pharmaceuticals Inc Azioni (PCSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Processa Pharmaceuticals Inc Azioni (PCSA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jan 27 '25 |
Buy |
0.80 |
87,200 |
69,542 |
87,200 |
| Young David | Pres. Research & Development |
Jan 27 '25 |
Buy |
0.80 |
124,500 |
99,289 |
205,405 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 27 '25 |
Buy |
0.80 |
43,500 |
34,691 |
43,500 |
1.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):